Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Meredith Slayter

Physician Assistant, Medical Indianapolis, IN Physician Assistant

NPI 1932468428 CMS profile 10491315

7250 Clearvista Dr Ste 355, Indianapolis, IN 46256

Open in the dashboard

General payments

$7,736

385 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Meredith Slayter of Indianapolis, IN is reported in the CMS Open Payments database as having received $7,736 across 385 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,094 98
2024 General $1,915 101
2023 General $1,967 102
2022 General $1,539 70
2021 General $220 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Meredith Slayter
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Meredith Slayter were reported at $2,094. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Meredith Slayter Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $220 $156 $41–$563 $132
2022 $1,539 $185 $55–$649 $149
2023 $1,967 $199 $58–$717 $160
2024 $1,915 $206 $62–$740 $164
2025 $2,094 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $1,050 47 payments
  2. GlaxoSmithKline, LLC. $997 63 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $616 29 payments
  4. Genzyme Corporation $586 29 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $568 27 payments
  6. Regeneron Healthcare Solutions, Inc. $565 25 payments
  7. Amgen Inc. $428 16 payments
  8. Mallinckrodt Hospital Products Inc. $330 11 payments
  9. Gilead Sciences, Inc. $312 17 payments
  10. Insmed, Inc. $297 16 payments
  11. Other $1,988 105 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,569 380 payments
  2. Education $167 5 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $586 29 payments
  2. GLASSIA $568 27 payments
  3. NUCALA $520 30 payments
  4. TRELEGY ELLIPTA $477 33 payments
  5. DUPIXENT Inflammation And Immunology $439 20 payments
  6. TEZSPIRE Respiratory $400 11 payments
  7. FASENRA $381 17 payments
  8. TEZSPIRE Inflammation $380 14 payments
  9. YUPELRI $344 23 payments
  10. ACTHAR $330 11 payments
  11. Other $3,729 187 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

1,903

Median for Physician Assistant: 241

Drug cost

$742,458

Median for Physician Assistant: $4,110

Branded share of claims

73.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 293 $227,614
Esbriet Pirfenidone Brand 13 $133,940
Spiriva Respimat Tiotropium Bromide Brand 95 $77,468
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 80 $64,329
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 69 $49,529
Breo Ellipta Fluticasone/Vilanterol Brand 82 $48,774
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 53 $26,724
Xarelto Rivaroxaban Brand 19 $17,190
Eliquis Apixaban Brand 15 $16,454
Symbicort Budesonide/Formoterol Fumarate Brand 40 $12,893

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$28,552

Medicare's payments for the services billed

Medicare patients

251

Average age 75

Services billed

442

163 women, 88 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 70%
Arthritis 49%
Ischemic heart disease 41%
Depression 35%
Chronic kidney disease 33%
Diabetes 29%
Heart failure 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $140
  • GENZYME CORPORATION $109
$249 — —
GLASSIA
  • Takeda Pharmaceuticals U.S.A., Inc. $208
$208 — —
YUPELRI
  • Mylan Specialty L.P. $140
$140 — —
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $135
$135 — —
TYVASO
  • United Therapeutics Corporation $129
$129 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

385 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record